Printer Friendly

Email to A Friend

Friday November 20, 1998

Israelis co-lead human-tissue study

WASHINGTON (JTA) -- Patients in need of tissue and organ transplants are one step closer to receiving laboratory-produced replac
As reported in the Nov. 6 issue of the journal Science, the team is the first to extract human embryonic stem cells -- the paren

The advance is expected to benefit transplant medicine, drug discovery and basic developmental biology. Doctors may use it in the future to treat victims of heart disease, diabetes, Parkinson's and Alzheimer's diseases, spinal cord injuries and some kinds of cancers.

James Thomson, a developmental biologist at the University of Wisconsin at Madison, headed an international research team that included Joseph Itskovitz, an Israeli in-vitro fertilization specialist and a member of the medical faculty at the Technion-Israel Institute of Technology in Haifa. Itskovitz provided the study with embryos and research assistance.

"We are searching now for a way to control the differentiation of the cells," Itskovitz said. "We cannot direct the cells changing into other human tissue cells -- it happens on its own randomly."

With so many scientific hurdles to cross, Thomson does not expect his labs to create specialized cells and tissues overnight. It will be at least 10 to 15 years before any treatments go to trial on humans.

Did you find this article interesting? Subscribe to our FREE newsletter and you'll be notified each week when "J." goes online. We'll tell you about the most important stories of the week and give you a link to each one.

This page contains a BETA version of Amazon contextual links. They are marked by the dashed underline.  Your purchases support our site. At times they point to items which are not related to the actual link. Please alert us by email if you discover objectionable links.